Aleniglipron Achieves Best-in-Class Oral GLP-1 Efficacy with Over 16% Weight Loss in Phase 2 Data—Low Discontinuation Rates Highlight Tolerability

Aleniglipron’s Phase 2 Results Set New Standard Among Oral GLP-1s

Structure Therapeutics (NASDAQ: GPCR) has made headlines today with updated Phase 2 results for aleniglipron, their investigational oral GLP-1 receptor agonist. The data show that aleniglipron achieved a placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg after 44 weeks. Notably, no evidence of a weight loss plateau emerged even with continued dosing through 56 weeks. These weight reductions not only eclipse results from prior oral GLP-1 trials but look competitive with popular injectable therapies.

Consistent Efficacy and Tolerability at Multiple Doses

Efficacy was robust across several dose ranges and studies. In the ongoing open-label extension (OLE), patients on 120 mg maintained a 16.2% (40.5 lbs) mean reduction at 56 weeks. Lower starting titration doses of 2.5 mg contributed to particularly low discontinuation rates due to adverse events: just 2.0% in the OLE and 3.4% in the body composition study over a median of 20 weeks.

Safety Profile and Discontinuation Rates Bolster Phase 3 Readiness

Safety continues to be a highlight: with over 625 participants, aleniglipron has so far shown no drug-induced liver injuries, persistent liver enzyme elevations, or QTc prolongation events. AEs, when present, were mainly mild-to-moderate GI symptoms, and lower titration appears to further ease tolerability burdens. Discontinuation due to AEs was less than 3.5% at lower starting doses and just 3.7% at high doses (120 mg+) between Weeks 28–44, far below rates often seen with injectable GLP-1 counterparts.

Phase 3 on Track—Potential for Market Leadership

After a Type B End-of-Phase 2 meeting with the FDA scheduled for Q2 2026, Structure plans to begin Phase 3 trials in the second half of the year, using a 2.5 mg starting dose and investigating doses up to 240 mg. The consistent efficacy, even beyond 56 weeks without plateau, and low rates of adverse event discontinuation position aleniglipron as a possible future backbone therapy for obesity—notably as an oral option potentially matching injectable standards.

Key Takeaways for Investors and Healthcare Stakeholders

With headline efficacy above 16% weight loss and a strong tolerability profile, aleniglipron could reshape the oral treatment landscape for obesity if these results are maintained in Phase 3. While much hinges on larger and longer trials—plus eventual regulatory review—the early results set a new benchmark for oral metabolic therapies. Investors and clinicians alike may want to follow subsequent trial data and the upcoming FDA meeting as Structure Therapeutics moves forward.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI